Effectiveness and Safety of Apatinib Mesylate Tablet in the Treatment of Advanced Solid Tumors


Effectiveness and Safety of Apatinib Mesylate Tablet in the Treatment of Advanced Solid Tumors


LIU Gang, WANG Junfeng, GUAN Yiguo, WANG Fang, XU Yuanchun

Tumour Hospital of Mudanjiang


American Journal of Clinical Research and Reviews

Angiogenesis is the most critical step in the development and progression of malignant tumors. Anti-tumor angiogenesis has become the most promising new strategy for tumor treatment. Rapidly growing tumor cells secrete a variety of vascular growth factors under hypoxia to stimulate tumor angiogenesis. One of the important growth factors is Vascular Endothelial Growth Factor (VEGF). Some small molecule compounds that inhibit VEGFR have been used to treat Tumors. In this study, we evaluated the effectiveness and safety of Apatinib Mesylate tablet in the treatment of advanced solid tumors. We found that Apatinib Mesylate tablet can treat advanced solid tumors.


Keywords: Apatinib Mesylate Tablet, Treatment, Advanced Solid Tumors

Free Full-text PDF


How to cite this article:
LIU Gang, WANG Junfeng, GUAN Yiguo, WANG Fang, XU Yuanchun. Effectiveness and Safety of Apatinib Mesylate Tablet in the Treatment of Advanced Solid Tumors. American Journal of Clinical Research and Reviews, 2020; 4:15. DOI:10.28933/ajcrr-2020-01-2206


References

1. Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag. 2006;2(3):213–219. doi:10.2147/vhrm.2006.2.3.213
2. Bielenberg DR, Zetter BR. The Contribution of Angiogenesis to the Process of Metastasis. Cancer J. 2015;21(4):267–273. doi:10.1097/PPO.0000000000000138
3. Fukumura D, Jain RK. Imaging angiogenesis and the microenvironment. APMIS. 2008;116(7-8):695–715. doi:10.1111/j.1600-0463.2008.01148.x
4. Bielenberg DR, Zetter BR. The Contribution of Angiogenesis to the Process of Metastasis. Cancer J. 2015;21(4):267–273. doi:10.1097/PPO.0000000000000138
5. Rajabi M, Mousa SA. The Role of Angiogenesis in Cancer Treatment. Biomedicines. 2017;5(2):34. Published 2017 Jun 21. doi:10.3390/biomedicines5020034
6. Al-Abd AM, Alamoudi AJ, Abdel-Naim AB, Neamatallah TA, Ashour OM. Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies – A review. J Adv Res. 2017;8(6):591–605. doi:10.1016/j.jare.2017.06.006
7. Ribatti D, Vacca A, Dammacco F. The role of the vascular phase in solid tumor growth: a historical review. Neoplasia. 1999;1(4):293–302. doi:10.1038/sj.neo.7900038
8. Chouaib S, Messai Y, Couve S, Escudier B, Hasmim M, Noman MZ. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol. 2012;3:21. Published 2012 Feb 23. doi:10.3389/fimmu.2012.00021
9. Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med. 2012;2(7):a006502. doi:10.1101/cshperspect.a006502
10. Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR. Antiangiogenic therapy for cancer: an update. Pharmacotherapy. 2012;32(12):1095–1111. doi:10.1002/phar.1147
11. Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?. Angiogenesis. 2010;13(1):1–14. doi:10.1007/s10456-009-9160-6
12. Rossi A1, Maione P, Ferrara ML, Sacco PC, Schettino C, Bareschino MA, Gridelli C. Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer. Curr Med Chem. 2009;16(30):3919-30.
13. Niu G, Chen X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets. 2010;11(8):1000–1017. doi:10.2174/138945010791591395
14. Thaker NG, Pollack IF. Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Rev Neurother. 2009;9(12):1815–1836. doi:10.1586/ern.09.116
15. Fallahi P, Di Bari F, Ferrari SM, et al. Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Devel Ther. 2015;9:3459–3470. Published 2015 Jul 3. doi:10.2147/DDDT.S72495
16. Zhou C. Multi-targeted tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: an era of individualized therapy. Transl Lung Cancer Res. 2012;1(1):72–77. doi:10.3978/j.issn.2218-6751.2011.12.04
17. J. V. Heymach, B. E. Johnson, J. A. Rowbottom, P. Fidias, C. Lu, D. Prager, J. Roubec, E. Csada, I. Dimery, and R. S. Herbst. A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC.Journal of Clinical Oncology 2005 23:16_suppl, 3023-3023
18. Corrales L, Nogueira A, Passiglia F, et al. Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib. Front Med (Lausanne). 2017;4:13. Published 2017 Feb 28. doi:10.3389/fmed.2017.00013
19. Yuankai Shi, Yan Yan, Handbook of Clinical Oncology. 2009: p. 422.
20. Yang C, Qin S. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma. Cancer Med. 2018;7(9):4570–4583. doi:10.1002/cam4.1664
21. Li X1, Xu A, Li H, Zhang B, Cao B, Huang J.. Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells. Biochim Biophys Acta Mol Basis Dis. 2018 May;1864(5 Pt A):1693-1701. doi: 10.1016/j.bbadis.2018.02.014. Epub 2018 Feb 24.
22. Li J, Zhao X, Chen L, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 2010;10:529. Published 2010 Oct 5. doi:10.1186/1471-2407-10-529
23. Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 2016;62:132–137. doi:10.1016/j.ejca.2016.03.081
24. Chie WC1, Chang KJ, Huang CS, Kuo WH. Quality of life of breast cancer patients in Taiwan: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and EORTC QLQ-BR23. Psychooncology. 2003 Oct-Nov;12(7):729-35.
25. Liu YJ1, Zhu GP, Guan XY.Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma. Oral Oncol. 2012 Jun;48(6):554-9. doi: 10.1016/j.oraloncology.2012.01.004. Epub 2012 Jan 30.